Search Dental Tribune

Johnson & Johnson single-shot COVID-19 vaccine receives FDA approval

E-Newsletter

The latest news in dentistry free of charge.

  • This field is for validation purposes and should be left unchanged.
Johnson & Johnson vaccine for COVID-19 has been 66 per cent effective at preventing moderate to severe COVID-19, and 85 per cent effective against severe illness, in their global trials.
Rajeev Chitguppi, Dental Tribune South Asia

By Rajeev Chitguppi, Dental Tribune South Asia

Sat. 27 February 2021

save

A key advisory group of the Food and Drug Administration experts, known as the Vaccines and Related Biological Products Advisory Committee, has recommended the Johnson & Johnson coronavirus vaccine's approval on Friday, 26 February. This will pave the way for the authorization of this vaccine and its availability at the earliest.

In a long discussion session, the Johnson & Johnson scientists argued that their single-shot vaccine was 66 percent effective at preventing moderate to severe COVID-19 and 85% effective against severe illness.

This FDA approval was expected because Johnson and Johnson's vaccine has met all the FDA criteria established last year for vaccine authorization, including a large-scale trial that proved the safety and efficacy and the company's ability to manufacture the COVID-19 vaccine consistently and safely.

The Johnson & Johnson vaccine is a viral vector vaccine that makes use of a harmless adenovirus viral vector – and replaces a small fragment of its genetic code with the genes of SARS-CoV-2 spike protein.

Leave a Reply

Your email address will not be published. Required fields are marked *

-